- GW Pharmaceuticals' (GWPH) Sativex, which is used to treat pain in patients with advanced cancer, has received Fast-Track designation from the FDA.
- As a cannabinoid medicine, Sativex is the only non-opioid treatment in Phase 3 development for patients who don't respond to, or experience negative side effects, with opioid medications, GW says.
- Shares are +6.8%. (PR)
at Benzinga.com (Jan 8, 2015)